Weight loss drug study for people with endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with stage I–III endometrial cancer and had surgery with no cancer left behind
- You are about to start or have recently started chemotherapy (carboplatin and paclitaxel) with or without radiation
- You are overweight (BMI of 27 or more) with a weight-related health condition, or have obesity (BMI 30 or more), or have type 2 diabetes with a BMI of 25 or more
- You are able and willing to give yourself daily injections of the study drug, or have someone who can help you
- You have insurance that covers the drug, or can pay for it yourself
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
This study tests whether a weight-loss medication (tirzepatide) can help shrink early-stage, low-grade endometrial cancer or atypical hyperplasia while you keep your uterus for future pregnancy. It is designed for women who are overweight and wish to preserve their fertility.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.